---
title: "GlucoTrack Executes Reverse Stock Split to Restructure Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297372174.md"
description: "GlucoTrack (GCTK) executed a one-for-15 reverse stock split effective August 28, 2026, reducing outstanding shares from ~11.97 million to ~798,144. This capital restructuring, approved by shareholders, aims to boost per-share metrics without changing aggregate net losses or authorized share limits. Trading resumes on a split-adjusted basis on August 31, 2026. Despite this move, TipRanks' AI analyst maintains a 'Neutral' rating due to weak financials, including zero revenue and accelerating cash burn."
datetime: "2026-08-28T21:50:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297372174.md)
  - [en](https://longbridge.com/en/news/297372174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297372174.md)
generator: "portal-rs"
---

# GlucoTrack Executes Reverse Stock Split to Restructure Shares

The latest announcement is out from GlucoTrack ( (GCTK) ).

GlucoTrack implemented a one-for-15 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on Aug. 28, 2026, following shareholder approval at its Aug. 18, 2026 annual meeting. The move consolidated every 15 issued and outstanding shares into one share, eliminated fractional shares through rounding up, and left the par value and total authorized common shares unchanged at 250 million.

The reverse split reduced the number of outstanding common shares from 11,972,157 to roughly 798,144, with corresponding adjustments to outstanding options, warrants, and their exercise prices. GlucoTrack’s stock will begin trading on a split-adjusted basis on Aug. 31, 2026 under the unchanged GCTK ticker, a capital structure change that significantly boosts the company’s per-share metrics while not altering its aggregate net loss figures.

**Spark’s Take on GCTK Stock**

According to Spark, TipRanks’ AI Analyst, GCTK is a Neutral.

Overall score is driven primarily by weak financial performance (no revenue, sizable losses, and accelerating cash burn with negative TTM equity) and poor technical positioning (trading below major moving averages with negative MACD). Corporate actions and financing provide some support to liquidity and strategy but also raise dilution risk, and valuation metrics are constrained by ongoing losses and no dividend.

To see Spark’s full report on GCTK stock,  
 click here. 

**More about GlucoTrack**

GlucoTrack, Inc. is a Delaware-incorporated company whose common stock trades under the ticker symbol GCTK. The company has a large authorized share base of 250 million common shares and uses stock options and warrants as part of its capital structure, indicating an equity-focused financing profile within the public markets.

**Average Trading Volume:** 11,044,273

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $3.4M

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)

## Related News & Research

- [GlucoTrack unit Lōkahi Therapeutics expands ai² platform into three divisions](https://longbridge.com/en/news/298326260.md)
- [GlucoTrack Inc trading halted, news pending](https://longbridge.com/en/news/297389332.md)
- [Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions | GCTK Stock News](https://longbridge.com/en/news/298328118.md)
- [GlucoTrack to enact 1-for-15 reverse stock split Aug. 31](https://longbridge.com/en/news/297181503.md)
- [Veidekke discloses 2026 share awards for senior executives](https://longbridge.com/en/news/298448651.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**